Anticipate generic drug launch
Find generic entry opportunities
Drug patents …
… from Kazakhstan to Kalamazoo
Manage your formulary budget
Proactively manage your pharmacy inventory
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Atomising nozzle and filter and spray generation device|
|Abstract:||A nozzle assembly for use in atomizing and generating sprays from a fluid. The nozzle assembly includes two members joined together. In one of the two members are formed one or more nozzle outlets, one or more fluid inlets, and a plurality of channels that form filter passageways. The nozzle outlets discharge fluid jets that impinge on one another to thereby atomize the fluid. Alternatively, an impact element or a vortex-generating structure can be used in the nozzle outlet to atomize the fluid.|
|Inventor(s):||Bartels; Frank (Waldbronn, DE), Bachtler; Wulf (Mainz, DE), Dunne; Stephen T. (Suffolk, GB), Eicher; Joachim (Karlsruhe, DE), Freund; Bernhard (Gau-Algesheim, DE), Hart; William B. (Suffolk, GB), Lessmoellmann; Christoph (Gernsbach, DE)|
|Assignee:||Boehringer Ingelheim International GmbH (DE) DMW (Technology) Ltd. (GB)|
Patent Claim Types:|
see list of patent claims
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Austria||183673||<disabled in preview>|
|Austria||312669||<disabled in preview>|
|Austria||421384||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.